cancer screening
Grail Q1 Revenues up 19 Percent Driven by Clinical Test Growth
Grail shared new results from the NHS trial of its Galleri screening test, which brought in $29.1 million in Q1, a 24 percent increase over the same quarter last year.
At the AACR annual meeting, investigators presented promising data across genomic and protein-based technologies, highlighting synergies that could improve performance.
Exact Sciences Q1 Revenues up 11 Percent as Firm Raises Full-Year Guidance
The company's screening revenue, which rose 14 percent year over year, was the main growth driver, though precision oncology test revenue also rose by 2 percent.
Guardant Health Builds Data Across Liquid Biopsy Menu, Ups Full-Year Guidance on Strong Q1 Earnings
Premium
The firm presented a slew of new data at the AACR annual meeting this week on its core therapy selection tests, its MRD assay, and its early cancer detection test.
AccuStem Sciences Partners With EmeritusDx on Molecular Lung Cancer Screening Test
The companies previously agreed to jointly develop AccuStem's recurrence predictor assay for patients with breast cancer.